Frontier Pharma: Alzheimer's Disease and Associated Indications - Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression

  • ID: 4302732
  • Report
  • Region: Global
  • 101 Pages
  • GBI Research
1 of 4

Summary

Alzheimer’s disease (AD) is the most common form of dementia - a generalized term used to describe loss of memory and other mental abilities that are severe enough to interfere with daily activities. Symptoms of dementia arise as a result of physical changes in the brain (Alzheimer’s Association, 2017b). AD accounts for approximately 60-80% of all cases of dementia. As with all forms of dementia, it is a progressive, neurodegenerative and currently incurable disease, with symptoms worsening over time.

AD is a multi-factorial disease resulting from interacting environmental, lifestyle and genetic factors. However, the greatest risk factor for AD development is advancing age. The vast majority of patients are aged 65 and older at diagnosis, although a small proportion develop AD between the ages of 30 and 64, which is termed early-onset AD.

The prevalence of AD is escalating rapidly, largely as a result of aging populations. This will amplify the already substantial societal and economic costs of the disease over the coming decades. However, despite this large market opportunity, there are no disease-modifying therapies currently available that are capable of halting, reversing or effectively modifying the course of disease progression. Treatment options are extremely limited and can only temporarily slow the worsening of symptoms (Alzheimer’s Association, 2017a; Yiannopoulou and Papageorgiou, 2013). Additionally, many aspects of the disease pathophysiology remain incompletely understood, and these knowledge gaps underlie the poor treatment options currently available to AD patients, and the failed attempts to improve on these therapies in clinical trials.

AD pipeline is large, with 646 products in active development. In addition, the level of first-in-class innovation within the pipeline is exceptionally high - 65.3% of products with a disclosed molecular target have been identified as first-in-class. In comparison, the pipeline for AD-associated indications is smaller and less innovative. There are 272 products in development across the four associated indications, and only 27.7% of those with a disclosed molecular target are first in class. However, the diversity of first-in-class targets identified is greater than that of the AD pipeline.

The deals landscape for AD and AD-associated indications has been fairly active over the past decade. The aggregate deal value for licensing deals reached $13.0 billion, while the aggregate deal value for co-development deals totaled $10.7 billion. Small molecule products and those targeting GPCRs have dominated the landscape in terms of both deal frequency and aggregate value.

The report "Frontier Pharma: Alzheimer’s Disease and Associated Indications - Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression" focuses on AD alongside four key associated behavioral and psychological indications: anxiety, depression, psychosis and insomnia. These four conditions are highly prevalent in AD and contribute substantially to the disease burden.

Moreover, this report allows you to:

  • Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, and diagnosis and treatment options.
  • Identify leading products and key unmet needs within the market.
  • Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
  • Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Individual matrix assessments are provided for targets identified in the pipeline for AD, anxiety, depression, psychosis and insomnia. Promising early-stage first-in-class targets are reviewed in greater detail.
  • Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

Scope

Unmet need is extremely high in AD, with behavioral and psychological complications contributing significantly to the disease burden

  • What are the most important etiological risk factors and pathophysiological processes implicated in AD?
  • What is the current treatment algorithm?
  • How common are anxiety, depression, psychosis and insomnia in AD?

The AD pipeline is large and contains a very high proportion of first-in-class product innovation

  • Which molecule types and molecular targets are most prominent across AD and its associated indications?
  • What are the connections, in terms of first-in-class innovation, between AD and its associated indications?
  • Which first-in-class targets are most promising?
  • How does the level of first-in-class innovation differ between products in development for anxiety, depression, psychosis and insomnia?
  • How does first-in-class target diversity differ by stage of development and molecular target class?

The deals landscape is active and dominated by G-protein coupled receptor (GPCR)-targeting products

  • Which indications attract the highest deal values?
  • How has deal activity fluctuated over the past decade?
  • Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

Reasons to buy

This report will allow you to:

  • Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, diagnosis and treatment options.
  • Identify leading products and key unmet needs within the market.
  • Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
  • Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Individual matrix assessments are provided for targets identified in the pipeline for AD, anxiety, depression, psychosis and insomnia. Promising early-stage first-in-class targets are reviewed in greater detail.
  • Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

1 Table of Contents

2 Executive Summary
2.1 Limited Treatment Options despite Large Market Opportunity
2.2 Exceptionally High Level of First-in-Class Innovation within Alzheimer’s Disease Pipeline
2.3 Active Deals Landscape Dominated by GPCR-Targeting Products

3 The Case for Innovation
3.1 Growing Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Product Developments Remain Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation in Alzheimer’s Disease
3.6 Research Report Guidance

4 Clinical and Commercial Landscape
4.1 Disease Overview
4.2 Classification of Dementia and Mild Cognitive Impairment
4.3 Symptoms, Disease Staging and Prognosis
4.4 Diagnosis
4.4.1 Mini Mental State Exam
4.4.2 Alzheimer’s Disease Assessment Scale - Cognitive
4.4.3 Alzheimer’s Disease Co-operative Study - Activities of Daily Living Inventory
4.4.4 Imaging Techniques
4.4.5 Lumbar Puncture
4.4.6 Blood Tests
4.5 Epidemiology
4.6 Etiology and Pathophysiology
4.6.1 Etiological Risk Factors
4.6.2 Pathophysiology
4.7 Management and Treatment of Alzheimer’s Disease
4.7.1 Pharmacological Intervention
4.7.2 Non-pharmacological Intervention
4.8 Overview of Marketed Products
4.9 Indications Associated with Alzheimer’s Disease
4.9.1 Anxiety
4.9.2 Depression
4.9.3 Psychosis
4.9.4 Insomnia

5 Assessment of Pipeline Product Innovation
5.1 Overview
5.2 Pipeline by Stage of Development and Molecule Type
5.2.1 Alzheimer’s Disease
5.2.2 Alzheimer’s-Disease-Associated Indications
5.3 Pipeline by Molecular Target
5.3.1 Alzheimer’s Disease
5.3.2 Alzheimer’s-Disease-Associated Indications
5.4 Comparative Distribution of Programs between the Market and Pipeline by Molecular Target Class
5.4.1 Alzheimer’s Disease
5.4.2 Alzheimer’s-Disease-Associated Indications
5.5 First-in-Class Programs Targeting Novel Molecular Targets
5.5.1 Alzheimer’s Disease
5.5.2 Alzheimer’s-Disease-Associated Indications
5.6 Ratio of First-in-Class Products to First-in-Class Targets
5.6.1 Alzheimer’s Disease
5.6.2 Alzheimer’s-Disease-Associated Indications
5.7 List of All First-in-Class Pipeline Programs

6 Signaling Network, Disease Causation and Innovation Alignment
6.1 Complexity of Signaling Networks
6.2 Signaling Pathways and First-in-Class Molecular Target Integration
6.3 First-in-Class Matrix Assessment

7 First-in-Class Target Profiles
7.1 Pipeline Programs Targeting Presenilin 1 for Alzheimer’s Disease
7.2 Pipeline Programs Targeting Apolipoprotein E for Alzheimer’s Disease
7.3 Pipeline Programs Targeting Apoptosis Regulator BAX for Alzheimer’s Disease
7.4 Pipeline Programs Targeting Sortilin for Alzheimer’s Disease
7.5 Pipeline Programs Targeting Metabotropic Glutamate Receptors 1, 2, 3, 4, 5 and 7 for Alzheimer’s Disease, Anxiety, Depression and Psychosis
7.6 Pipeline Programs Targeting Sodium Dependent Neutral Amino Acid Transporter B(0) AT2 for Depression and Anxiety
7.7 Pipeline Programs Targeting Cytochrome P450 1A2 for Insomnia and Anxiety

8 Strategic Consolidations
8.1 Industry-Wide First-in-Class Deals
8.2 Licensing Deals
8.2.1 Deals by Region, Value and Year
8.2.2 Deals by Indication
8.2.3 Deals by Stage of Development and Value
8.2.4 Deals by Molecule Type, Molecular Target and Value
8.2.5 List of Deals with Deal Values Exceeding $100m
8.3 Co-development Deals
8.3.1 Deals by Region, Value and Year
8.3.2 Deals by Indication
8.3.3 Deals by Stage of Development and Value
8.3.4 Deals by Molecule Type, Molecular Target and Value
8.3.5 List of Deals with Deal Values Exceeding $100m
8.4 First-in-Class Programs with and without Prior Involvement in Licensing and Co-development Deals

9 Appendix
9.1 References
9.2 Abbreviations
9.3 Research Methodology
9.3.1 Data integrity
9.3.2 Innovative and meaningful analytical techniques and frameworks:
9.3.3 Evidence based analysis and insight:
9.4 Secondary Research
9.4.1 Market Analysis
9.4.2 Pipeline Analysis
9.4.3 First-in-Class Matrix Assessment
9.4.4 First-in-Class Target Profiles
9.4.5 Licensing and Co-Development Deals

List of Tables
Table 1: Alzheimer’s Disease and Associated Indications, Global, Common Forms of Dementia, 2017
Table 2: Alzheimer’s Disease and Associated Indications, Global, Common Alzheimer’s Disease Symptoms by Disease Stage, 2017
Table 3: Alzheimer’s Disease and Associated Indications, Global, Scoring for Mini-Mental State Exam, 2017
Table 4: Alzheimer’s Disease and Associated Indications, Global, Scoring for the Alzheimer’s Disease Assessment Scale-Cognitive , 2017
Table 5: Alzheimer’s Disease and Associated Indications, Global, Common Physical and Psychological Symptoms Associated with Anxiety Disorders, 2017
Table 6: Alzheimer’s Disease and Associated Indications, Global, Common Forms of Depression, 2017
Table 7: Alzheimer’s Disease and Associated Indications, Global, Key Features of Presenilin 1, 2017
Table 8: Alzheimer’s Disease and Associated Indications, Global, Pipeline Programs Targeting Presenilin 1, 2017
Table 9: Alzheimer’s Disease and Associated Indications, Global, Key Features of Apolipoprotein E, 2017
Table 10: Alzheimer’s Disease and Associated Indications, Global, Pipeline Programs Targeting Apolipoprotein E, 2017
Table 11: Alzheimer’s Disease and Associated Indications, Global, Key Features of Apoptosis Regulator BAX, 2017
Table 12: Alzheimer’s Disease and Associated Indications, Global, Pipeline Programs Targeting Apoptosis Regulator BAX, 2017
Table 13: Alzheimer’s Disease and Associated Indications, Global, Key Features of Sortilin, 2017
Table 14: Alzheimer’s Disease and Associated Indications, Global, Pipeline Programs Targeting Sortilin, 2017
Table 15: Alzheimer’s Disease and Associated Indications, Global, Key Features of Metabotropic Glutamate Receptor 1, 2017
Table 16: Alzheimer’s Disease and Associated Indications, Pipeline Programs Targeting Metabotropic Glutamate Receptor 1, 2017
Table 17: Alzheimer’s Disease and Associated Indications, Global, Key Features of Metabotropic Glutamate Receptor 2, 2017
Table 18: Alzheimer’s Disease and Associated Indications, Pipeline Programs Targeting Metabotropic Glutamate Receptor 2, 2017
Table 19: Alzheimer’s Disease and Associated Indications, Global, Key Features of Metabotropic Glutamate Receptor 3, 2017
Table 20: Alzheimer’s Disease and Associated Indications, Pipeline Programs Targeting Metabotropic Glutamate Receptor 3, 2017
Table 21: Alzheimer’s Disease and Associated Indications, Global, Key Features of Metabotropic Glutamate Receptor 4, 2017
Table 22: Alzheimer’s Disease and Associated Indications, Pipeline Programs Targeting Metabotropic Glutamate Receptor 4 (GRM4), 2017
Table 23: Alzheimer’s Disease and Associated Indications, Global, Key Features of Metabotropic Glutamate Receptor 5, 2017
Table 24: Alzheimer’s Disease and Associated Indications, Pipeline Programs Targeting Metabotropic Glutamate Receptor 5, 2017
Table 25: Alzheimer’s Disease and Associated Indications, Global, Key Features of Metabotropic Glutamate Receptor 7 (GRM7), 2017
Table 26: Alzheimer’s Disease and Associated Indications, Pipeline Programs Targeting Metabotropic Glutamate Receptor 7 (GRM7), 2017
Table 27: Alzheimer’s Disease and Associated Indications, Global, Sodium Dependent Neutral Amino Acid Transporter B0 AT2, 2017
Table 28: Alzheimer’s Disease and Associated Indications, Global, Pipeline Programs Targeting Sodium Dependent Neutral Amino Acid Transporter B0 AT2, 2017
Table 29: Alzheimer’s Disease and Associated Indications, Global, Key Features of Cytochrome P450 1A2, 2017
Table 30: Alzheimer’s Disease and Associated Indications, Global, Pipeline Programs Targeting Cytochrome P450 1A2, 2017

List of Figures
Figure 1: Alzheimer’s Disease and Associated Indications, Global, US, Innovation Trends in Product Approvals, 1987-2014
Figure 2: Alzheimer’s Disease and Associated Indications, US, Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006-2013
Figure 3: Alzheimer’s Disease and Associated Indications, Global, Alzheimer’s Disease Market by Molecular Target, 2017
Figure 4: Alzheimer’s Disease and Associated Indications, Global, Alzheimer’s Disease Associated Indications Market by Molecular Target, 2017
Figure 5: Alzheimer’s Disease and Associated Indications, Global, Pipeline by Therapy Area, 2017
Figure 6: Alzheimer’s Disease, Global, Pipeline by Stage of Development and Molecule Type, 2017
Figure 7: Anxiety, Depression, Psychosis and Insomnia, Global, Pipelines by Stage of Development, 2017
Figure 8: Anxiety, Depression, Psychosis and Insomnia, Global, Pipelines by Molecule Type, 2017
Figure 9: Alzheimer’s Disease, Global, Pipeline by Molecular Target, 2017
Figure 10: Anxiety, Depression, Psychosis and Insomnia, Global, Pipelines by Molecular Target, 2017
Figure 11: Alzheimer’s Disease, Global, Pipeline and Marketed Products by Molecular Target Class, 2017
Figure 12: Alzheimer’s-Disease-Associated Indications, Global, Pipeline and Marketed Products by Molecular Target Class, 2017
Figure 13: Alzheimer’s Disease, Global, Pipeline by Molecular Target Class, First-in-Class Status and Stage of Development, 2017
Figure 14: Alzheimer’s Disease, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Products by Stage of Development and Molecular Target Class, 2017
Figure 15: Alzheimer’s-Disease-Associated Indications, Global, Pipeline by Molecular Target Class, First-in-Class Status and Stage of Development, 2017
Figure 16: Alzheimer’s-Disease-Associated Indications, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Products by Stage of Development and Molecular Target Class, 2017
Figure 17: Alzheimer’s Disease, Global, Ratio of First-in-Class Products to First-in-Class Targets for Pipeline Products by Stage of Development and Molecular Target Class, 2017
Figure 18: Alzheimer’s-Disease-Associated Indications, Global, Ratio of First-in-Class Products to First-in-Class Targets for Pipeline Products by Stage of Development and Molecular Target Class, 2017
Figure 19: Alzheimer’s Disease and Associated Indications, Global, List of All First-in-Class Pipeline Programs, 2017 (part 1)
Figure 20: Alzheimer’s Disease and Associated Indications, Global, List of All First-in-Class Pipeline Programs, 2017 (part 2)
Figure 21: Alzheimer’s Disease and Associated Indications, Global, List of All First-in-Class Pipeline Programs, 2017 (part 3)
Figure 22: Alzheimer’s Disease and Associated Indications, Global, List of All First-in-Class Pipeline Programs, 2017 (part 4)
Figure 23: Alzheimer’s Disease and Associated Indications, Global, List of All First-in-Class Pipeline Programs, 2017 (part 5)
Figure 24: Alzheimer’s Disease and Associated Indications, Global, List of All First-in-Class Pipeline Programs, 2017 (part 6)
Figure 25: Alzheimer’s Disease and Associated Indications, Global, List of All First-in-Class Pipeline Programs, 2017 (part 7)
Figure 26: Alzheimer’s Disease and Associated Indications, Global, List of All First-in-Class Pipeline Programs, 2017 (part 8)
Figure 27: Alzheimer’s Disease and Associated Indications, Global, List of All First-in-Class Pipeline Programs, 2017 (part 9)
Figure 28: Alzheimer’s Disease and Associated Indications, Global, List of All Pipeline Programs, 2017 (part 10)
Figure 29: Alzheimer’s Disease and Associated Indications, Global, First-in-Class Matrix Assessment for Alzheimer’s Disease Products, 2017
Figure 30: Alzheimer’s Disease and Associated Indications, Global, First-in-Class Matrix Assessment for Anxiety Products, 2017
Figure 31: Alzheimer’s Disease and Associated Indications, Global, First-in-Class Matrix Assessment for Depression Products, 2017
Figure 32: Alzheimer’s Disease and Associated Indications, Global, First-in-Class Matrix Assessment for Psychosis Products, 2017
Figure 33: Alzheimer’s Disease and Associated Indications, Global, First-in-Class Matrix Assessment for Insomnia Products, 2017
Figure 34: Alzheimer’s Disease and Associated Indications, Global, Industry-Wide Licensing Deals by First-in-Class Status and Stage of Development, 2006-2014
Figure 35: Alzheimer’s Disease and Associated Indications, Global, Industry-Wide Licensing Deals by Deal Value, Upfront Payment Value, Stage of Development and First-in-Class Status, 2006-2014
Figure 36: Alzheimer’s Disease and Associated Indications, Global, Licensing Deals by Region, Value and Year, 2006-2017
Figure 37: Alzheimer’s Disease and Associated Indications, Global, Licensing Deals by Indication and Deal Value, 2006-2017
Figure 38: Alzheimer’s Disease and Associated Indications, Global, Licensing Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006-2017
Figure 39: Alzheimer’s Disease and Associated Indications, Global, Number and Aggregate Deal Value of Licensing Deals by Molecule Type, 2006-2017
Figure 40: Alzheimer’s Disease and Associated Indications, Global, Number and Aggregate Deal Value of Licensing Deals by Molecular Target, 2006-2017
Figure 41: Alzheimer’s Disease and Associated Indications, Global, Licensing Deals Exceeding $100m in Value, 2006-2017
Figure 42: Alzheimer’s Disease and Associated Indications, Global, Co-development Deals by Region, Value and Year, 2006-2017
Figure 43: Alzheimer’s Disease and Associated Indications, Global, Co-development Deals by Indication and Deal Value, 2006-2017
Figure 44: Alzheimer’s Disease and Associated Indications, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2017
Figure 45: Alzheimer’s Disease and Associated Indications, Global, Number and Aggregate Deal Value of Co-development Deals by Molecule Type, 2006-2017
Figure 46: Alzheimer’s Disease and Associated Indications, Global, Number and Aggregate Deal Value of Co-development Deals by Molecular Target, 2006-2017
Figure 47: Alzheimer’s Disease and Associated Indications, Global, Co-development Deals Exceeding $100m in Value, 2006-2017

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll